NASDAQ : BLUE

bluebird bio, Inc.

$4.97 USD

$0 (0.0%)

Volume
1.25M
Average Volume
576.32K
Market Capitalization
$48.67M
P/E Ratio
-0.20
Dividend Yield
0.00%
Price Target
$12.50
Year High
$28.60
Year Low
$3.20
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.48
Company Overview

NASDAQ

Andrew Obenshain

Biotechnology

Healthcare

BLUE

248

US

USD

https://www.bluebirdbio.com

339 499 9300

096ESC017

0001293971

Liquidity Metrics

-11.36

0.48

0.28

0.19

0.00

Sales & Valuation

$83.81M

0.58

-1.53

-0.19

-27.10

Profitability

-$24.84

-$240.72M

-287.23%

-287.14%

-295.35%

-52.30%

P/E Metrics

-0.20

0.00

0.00

Analyst Price Target & Rating

$12.50

$25.00

$5.00

N/A

0/5

37 Analysts

-60.24%

Financial Health Scores

-23.54

3/9

-$140.55M

$295.96M

$353.82M

-$177.13M

Key Metrics (TTM)

$344.6M

4.11

-2.20

0.48

-295.35%

-82.55%

-499.88%

-539.61%

198 days

Company Executives
Name Title
Andrea Walton Chief People Officer
Richard Colvin Chief Medical Officer
Andrew Obenshain President, Chief Executive Officer & Director
Thomas J. Klima Chief Commercial & Operating Officer
Joseph D. Vittiglio Chief Legal & Business Officer and Secretary
Kasra Kasraian Senior Vice President of Quality, Regulatory & CMC Sciences
Oliver James Sterling Chief Financial Officer & Principal Accounting Officer
Scott Shoemaker Senior Vice President of Technical Operations
Poll Results

No votes yet today — be the first to share your view!

About bluebird bio, Inc. (NASDAQ:BLUE) Stock

bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurren ... tly, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.

FULTON FINANCIAL MERGES ITS BLUE FOUNDRY BANK SUBSIDIARY INTO FULTON BANK, N.A.

2026-07-13 08:30:00

Former Blue Foundry Bank customers now have access to full suite of   Fulton Bank products, services and financial centers LANCASTER, Pa., July 13, 2026 /PRNewswire/ -- Fulton Financial Corporation (NASDAQ: FULT) ("Fulton") announced the merger of Blue Foundry Bank with and into Fulton Bank, N.A.

Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting

2026-06-04 16:20:00

Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Leading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not Warranted BRISBANE, Calif., June 4, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued a reminder to all Pacira stockholders to vote the  BLUE proxy card "FOR" each of Pacira's three highly qualified director nominees in advance of the Company's upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026.

Intermedia Launches Cloud Calling for UNIVERGE BLUE with KDDI, Significantly Expanding Nationwide UCaaS Availability in Japan

2026-06-03 09:00:00

New capability enables multi-site Japanese numbering without external equipment, making full-cloud communications easier to deploy nationwide New capability enables multi-site Japanese numbering without external equipment, making full-cloud communications easier to deploy nationwide

ISS and Glass Lewis Support BIMIZCI's Case for Change at Medallion Financial. Both Recommend Stockholders Vote on the BLUE Proxy Card FOR Election of Two BIMIZCI Nominees to Medallion Board

2026-05-29 13:21:00

MINNEAPOLIS--(BUSINESS WIRE)---- $MFIN #ActivistInvesting--BIMIZCI Fund LLC, Warnke Investments LLC, ZimCal Asset Management, LLC and Stephen Hodges (collectively, "BIMIZCI" or "we"), long-standing holders of Medallion Financial Corp. (NASDAQ: MFIN) ("Medallion" or the "Company") trust preferred securities and currently the 4th largest institutional stockholder with 500,250 shares, announced today that both leading independent proxy advisory firms, Institutional Shareholder Services ("ISS") and Glass, Lewis & Co. ("Gla.

BLUE OWL CAPITAL INC. INVESTOR ALERT: Haeggquist & Eck, LLP Announces Investigation of Blue Owl Capital Inc.'s Directors and Officers for Breach of Fiduciary Duties – OWL

2026-05-19 21:40:00

SAN DIEGO--(BUSINESS WIRE)---- $OWL #BlueOwl--Haeggquist & Eck, LLP Announces Investigation of Blue Owl Capital Inc.'s Directors and Officers for Breach of Fiduciary Duties.

BLUE WATER ACQUISITION CORP. IV ANNOUNCES LETTER OF INTENT FOR A PROPOSED ACQUISITION OF MAHA CAPITAL AB SUBSIDIARIES, CREATING A PUBLIC PLATFORM WITH VENEZUELAN ENERGY EXPOSURE AND HIGH-GROWTH AI FINTECH BUSINESS

2026-04-28 08:00:00

NEW YORK, April 28, 2026 /PRNewswire/ -- Blue Water Acquisition Corp. IV (NYSE: BWIV) ("BWIV"), a publicly listed special purpose acquisition company (the "Company"), today announced that it has entered into a letter of intent ("LOI") to acquire substantially all of Maha Capital AB ("Maha") subsidiaries inclusive of their respective assets and contracts expected to result in the formation of a publicly traded company listed on the New York Stock Exchange (NYSE). The Company will be headquartered in New York City and will create a differentiated portfolio of energy and financial technology assets.

Frequently Asked Questions

What is the current bluebird bio, Inc. (BLUE) stock price?

bluebird bio, Inc.(NASDAQ:BLUE) stock price is $4.97 in the last trading session. During the trading session, BLUE stock reached the peak price of $28.6 while $3.2 was the lowest point it dropped to. The percentage change in BLUE stock occurred in the recent session was 0.0% while the dollar amount for the price change in BLUE stock was $0.

BLUE's industry and sector of operation?

The NASDAQ listed BLUE is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BLUE?

Andrea Walton | Chief People Officer
Richard Colvin | Chief Medical Officer
Andrew Obenshain | President, Chief Executive Officer & Director
Thomas J. Klima | Chief Commercial & Operating Officer
Joseph D. Vittiglio | Chief Legal & Business Officer and Secretary

How many employees does BLUE have?

Number of BLUE employees currently stands at 248. BLUE operates from 60 Binney Street, Cambridge, MA 02142, US.

Link for BLUE official website?

Official Website of BLUE is: https://www.bluebirdbio.com

How do I contact BLUE?

BLUE could be contacted at phone #339 499 9300 and can also be accessed through its website. BLUE operates from 60 Binney Street, Cambridge, MA 02142, US.

How many shares of BLUE are traded daily?

The average number of BLUE shares traded daily for last 3 months was 576.32K.

What is the market cap of BLUE currently?

The market value of BLUE currently stands at $48.67M with its latest stock price at $4.97